Vorasidenib: A Targeted Therapy For Glioma
- Some people with slower-growing gliomas now have a targeted treatment option after surgery. Instead of undergoing more aggressive treatments like chemotherapy or radiation, some patients with a specific genetic mutation can take a once-daily pill called vorasidenib to help keep their cancer under control.
- Vorasidenib targets a specific genetic change called an IDH mutation. This mutation helps some gliomas grow, and the drug is designed to block it.
- Dr. Yoshua Esquenazi, a neurosurgeon at UTHealth Houston, says he has seen many patients take the medication for years without requiring a more aggressive or invasive treatment approach.
- Vorasidenib works only for gliomas with an IDH mutation, so doctors must test tumor tissue before treatment. In clinical trials, the drug helped delay tumor growth and reduced the need for additional treatments such as radiation, chemotherapy, or repeat surgery.
Now, thanks to precision medicine, there is another path for some patients.
Read MoreGlioma Types & Targeted Therapies
Gliomas are a large group of tumors that start in the brain’s support cells, called glial cells. The group includes astrocytomas and oligodendrogliomas, and most faster-growing brain tumors are gliomas. Glioblastoma, the most aggressive type, is the most common malignant brain tumor in adults.
Not every glioma behaves the same way. Doctors now classify these tumors partly by their genes, and one gene change in particular has reshaped how some gliomas are treated.
Scientists have discovered that certain changes in the DNA of cells, known as mutations, like the IDH mutation, can act as fuel, helping these tumors grow and spread. Recently, scientists have developed drugs to target this gene mutation, which can lead to better outcomes for patients and a new way to treat this disease.
Dr. Esquenazi explains that the discovery, made almost 20 years ago, is what allowed scientists to develop IDH inhibitors, “medications specifically targeted to that mutation.”
Normally, IDH enzymes help cells process molecules involved in energy production. When the gene is mutated, the enzyme starts making a different molecule, called 2-hydroxyglutarate (2-HG), which disrupts how genes are switched on and off inside the cell. Scientists consider the IDH mutation one of the earliest events in the development of these tumors, which is why blocking it became an attractive target.
IDH inhibitors are medications designed to target the mutated IDH enzyme specifically.
The First Targeted Pill for These Gliomas
On August 6, 2024, the U.S. Food and Drug Administration approved vorasidenib (brand name Voranigo) as an option after surgery for adults and children over the age of 12 with grade 2 glioma (astrocytoma or oligodendroglioma) that carries an IDH mutation.
It was the first FDA-approved drug treatment for this group of patients. Adults take it as a 40 mg pill once a day.
The approval was based on the Phase 3 INDIGO clinical trial, which enrolled 331 people who had surgery but no chemotherapy or radiation.
The results were promising:
- People on vorasidenib went a median of 27.7 months before their tumor grew, compared with 11.1 months on placebo, a 61% lower risk of progression.
- At two years, 83.4% of people on vorasidenib had not needed another treatment, such as radiation, chemotherapy, or more surgery, compared with 27% on placebo.
“These patients can now take a pill that is taken once a day,” Dr. Esquenazi says, adding that he’s seen many patients stay on an IDH inhibitor for years with good results.
Vorasidenib for Glioma: What to Know
In the INDIGO trial, the most common side effects associated with vorasidenib were fatigue, headache, COVID-19 infection, muscle and joint pain, diarrhea, nausea, and seizures.
Serious (grade 3 or higher) side effects occurred in 22.8% of people on vorasidenib and 13.5% on placebo.
Vorasidenib only works for tumors with an IDH mutation, so the tumor tissue has to be tested first. In the trial, mutation status was confirmed with an FDA-approved test.
INDIGO’s main goal was to measure how long tumors stayed under control, not how long people lived, so complete survival data is not yet available. People on placebo in the trial could also switch to vorasidenib once their tumors grew, which will make long-term survival comparisons harder to interpret.
The trial also didn’t include people with grade 3 or 4 tumors or people who had already had radiation or chemotherapy, so researchers are still working out where the drug fits for them.
Questions To Ask Your Doctor
- Has my tumor been tested for an IDH mutation, and what did the results show?
- Am I a candidate for vorasidenib, or for a clinical trial?
- What are the risks and benefits of vorasidenib compared to other options, like radiation or watchful waiting?
- How often will I need scans and blood tests while I’m on targeted therapy?
Learn more about SurvivorNet's rigorous medical review process.
